Dendreon’s Reached Orbit… Now Who’s Next?
by Robert Williams, Publisher
When the opening bell rang on Tuesday morning, as the broader market sagged, shares of Dendreon Corp. (Nasdaq: DNDN) sprinted out of the gates, rising by 5.7%.
Unless you live in a cave, you should know about this biotech stock.
Back in April, shares went “parabolic,” blasting 454% higher during the month.
(That’s not a typo. The stock increased almost five-fold over the course of a single month, rendering the S&P 500′s 10% gain over the same period completely insignificant.)
With an impressive move like that, you might think the run is over. But shares will likely head higher still…
You see, Dendreon is blazing a brand new path in biotech. Its prostate cancer drug, Provenge, which it just submitted to the FDA for approval, is the first of its kind. Known as an active immunotherapy, it trains a patient’s immune system to attack deadly cancer cells instead of relying on surgery, radiation treatment, or an injected drug to wipe them out.
In laymen’s terms, Provenge is a cancer vaccine. And the growth for such vaccines is expected to soar by roughly 30% per year through 2012, according to the research firm, RNCOS, Inc. At such a rapid rate, cancer vaccines will account for one-quarter of the global vaccine market.
The good news is that Dendreon isn’t the only player in the space. After all, we’ll need more than one immunotherapy to help combat the 12 million new cancer patients annually. And Dendreon’s success is opening the door for other companies developing immunotherapy treatments that might not otherwise get a chance.
Today, our small and micro-cap specialist Louis Basenese reveals one such company, delivering promising early clinical results, which he believes could ultimately lead to similar profits like those of investors in Dendreon Corp.
A 454% return or more? That’s a bold claim, no doubt. So check in with Louis to find out how it’s possible.
Ahead of the tape,
Robert Williams
Related Investment U Articles:
- Why This Major FDA Approval Could Pave the Way for These Five Biotechs
- Danger Ahead for Dendreon? Consider This Micro Cap Instead
- Three Biotech Stocks You Should Sell Before 2012
- The Emerging Market Healthcare Trend That Nobody is Talking About
- Four Potential Small-Cap Superstars to Break Out of The Healthcare Sector
One Response to “Dendreon’s Reached Orbit… Now Who’s Next?”
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy. |
 |
In addition to once being a full-time trader of equities and equity derivatives, Robert Williams has served as the lead financial analyst for a Forbes top-50 private corporation and an analyst for the endowment of a major academic institution. He's also been profiled in such books as Trade with Passion and Purpose and Alexander Green's The Secret of Shelter Island. 
How-where can I buy Northwestbiotherapeutics
Reply